Baseline blood amylin levels predict longitudinal cognitive decline in participants at risk for or with mild cognitive impairment and dementia

Amylin is a systemic hormone that is co‐secreted with insulin from pancreatic β‐cells that co‐aggregates with parenchymal and vascular b‐amyloid in the CNS. Cross‐sectional data shows that higher CSF and blood amylin levels are associated with increased frequency of cognitive impairment and dementia. The present study sought to determine whether baseline blood amylin levels are associated with longitudinal cognitive decline.